Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections

Annals of Pharmacotherapy

Volumn 38, Issue 9, 2004, Pages 1377-1382

  Kopp, Brian J ^a   Nix, David E ^a   Armstrong, Edward P ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Methicillin resistance; Staphylococcus aureus

Indexed keywords

METICILLIN; VANCOMYCIN;

ADOLESCENT; ADULT; AGE; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; ECONOMIC ASPECT; FEMALE; HOSPITAL COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE; TREATMENT OUTCOME;

ACADEMIC MEDICAL CENTERS; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTH CARE COSTS; HUMANS; LENGTH OF STAY; MALE; METHICILLIN; METHICILLIN RESISTANCE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 4143111197     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E028     Document Type: Article

References (31)

1. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999;20:303-16.
2. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998;158:522-7.
3. Centers for Disease Control and Prevention NNIS System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-June 2001, issued August 2001. Am J Infect Control 2001;29:404-21.
4. Paladino JA. Pharmacoeconomics of antimicrobial therapy. Am J Health Syst Pharm 1999;56(22 suppl 3):S25-8.
5. Birmingham MC, Hassett JM, Schentag JJ, Paladino JA. Assessing antibacterial pharmacoeconomics in the intensive care unit. Pharmacoeconomics 1997;12:637-47.
6. Ǵlvez-Vargas R, Bueno-Cavanillas A, Garcia-Martín M. Epidemiology, therapy and costs of nosocomial infection. Pharmacoeconomics 1995;7: 128-40.
7. Dunagan C, Woodward RS, Medoff G, Gray JL, Casabar E, Smith MD, et al. Antimicrobial misuse in patients with positive blood cultures. Am J Med 1989;87:253-9.
8. Carbon C. Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci. J Antimicrob Chemother 1999;44:31-6.
9. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
10. Linden PK, Pasculle AW, Maflez R, Kramer DJ, Fung JJ, Pinna AD, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663-70.
11. Einarsson S, Kristjansson M, Kristinsson KG, Kjartansson G, Jonsson S. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: a case-control study. Scand J Infect Dis 1998;30:253-6.
12. Nathwani D, Malek M. Cost considerations in the evaluation of new therapies for gram-positive bacteria. Int J Antimicrob Agents 1999;13:71-8.
13. Soriano A, Martinez JA, Mensa J, Marco J, Almela M, Moreno-Martinez A, et al. Pathogenic significance of methicillin resistance for patients with S. aureus bacteremia. Clin Infect Dis 2000;30:368-73.
14. Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med 1998;158:182-9.
15. González C, Rubio M, Romero-Vivas J, González M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29:1171-7.
16. Wisplinghoff H, Seifert H, Coimbra M, Wenzel RP, Edmond MB. Systemic inflammatory response syndrome in adult patients with nosocomial bloodstream infection due to Staphylococcus aureus. Clin Infect Dis 2001;33:733-6.
17. McClelland RS, Fowler VG, Sanders LL, Gottlieb G, Kong LK, Sexton DJ, et al. Staphylococcus aureus bacteremia among elderly vs younger adult patients: comparison of clinical features and mortality. Arch Intern Med 1999;159:1244-7.
18. Gleason TG, Crabtree TD, Pelletier SJ, Raymond DP, Karchmer TB, Pruett TL, et al. Prediction of poorer prognosis by infection with antibiotic-resistant gram-positive cocci than by infection with antibiotic-sensitive strains. Arch Surg 1999;134:1033-40.
19. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002;162:2229-35.
20. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999;20:408-11.
21. Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995;21:1417-23.
22. Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-8.
23. Mekontso-Dessap A, Kirsch M, Brun-Buisson C, Loisance D. Poststernotomy mediastinitis due to Staphylococcus aureus: comparison of methicillin-resistant and methicillin-susceptible cases. Clin Infect Dis 2001;32:877-83.
24. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta analysis. Clin Infect Dis 2003;36:53-9.
25. Boyce JM, Landry M, Deetz TR, DuPont HL. Epidemiologie studies of an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections. Infect Control 1981;2:110-6.
26. Vincent JL, Moreno R, Takala J, Willatts S, DeMendonca A, Braining H, et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707-10.
27. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674-80.
28. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34:1227-31.
29. Garner JS, Hospital Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention. Guideline for isolation precautions in hospital. Infect Control Hosp Epidemiol 1996;17:53-80.
30. Shlaes DM, Gerding DN, John JF, Craig WA, Bornstein DL, Duncan RA, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584-99.
31. Arnold MS, Dempsey JM, Fishman M, McAuley PJ, Tibert C, Vallande NC. The best hospital practices for controlling methicillin-resistant Staphylococcus aureus: on the cutting edge. Infect Control Hosp Epidemiol 2002;23:69-76.